Thursday, July 29, 2010

New tablet for type 2 diabetes sufferers.....

We know that, Vildagliptin (previously identified as LAF237, trade name Galvus) is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.
Novartis has since withdrawn its intent to submit vildagliptin to the FDA, as of July 2008.  The FDA  had demanded additional clinical data before it could approve vildagliptin including extra evidence that skin lesions and kidney impairment seen during an early study on animals have not occurred in human trials.While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU.
Now as per the claim by Prof Greg Fulcher of Director of diabetes services at Sydney's Royal North Shore Hospital, Galvus, will lower blood sugar effectively without increasing body weight and conclude that this medicine will "significantly increase" the likelihood of diabetes 2 patients reaching blood glucose targets of less than seven per cent (together, the clinical effectiveness and good tolerability of Galvus) and there by reinforce its potential for helping patients with type 2 diabetes and their doctors to better manage this chronic disease. These tablets would be taken once or twice in a day. The details of the treatment are to appear on the Pharmaceutical Benefits Scheme from August 1., in Australia.

No comments: